EnsiliTech, a UK-based biotech startup developing new methods to stabilize medicines, has raised £4.5 million in seed funding to accelerate the rollout of its “Ensiliication” technology, which eliminates the need for refrigerated transport.
The oversubscribed round was led by Eos Advisory and joined by Calculus Capital, Empirical Ventures, Fink Family Office, QantX, Angel Investors Bristol, HERmesa, Penn Park Capital, chANGELS, and several individual angels.
EnsiliTech’s technology replaces the decades-old “cold chain” infrastructure that underpins global drug storage and distribution. Today, transporting vaccines and biopharmaceuticals requires strict refrigeration, a process estimated to cost the industry £26 billion annually due to failures and inefficiencies.
The company’s solution uses “Ensiliication,” a process that coats vaccines, antibodies, and other biologics in a thin, silica-based shell. This stabilizes the medicine at temperatures up to 50°C, protecting it against heat and humidity while maintaining efficacy. When ready to use, the silica layer cracks open, leaving the treatment intact.
Ensiliication has the potential to change global access to life-saving medicines by removing one of the biggest barriers: the need for refrigeration
Co-founder and CEO of EnsiliTech, Dr. Asel Sartbaeva
The funding will help EnsiliTech expand infrastructure, grow its team, and generate the validation data required to integrate ”Ensiliication” into pharmaceutical manufacturing.
EnsiliTech is a Bristol-based startup, which spun out from the University of Bath in 2022. It is a pioneering biotechnology company dedicated to enhancing the stability and accessibility of biopharmaceuticals.
